{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:13:47Z","timestamp":1789820027603,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A subset of patients with Lynch Syndrome demonstrates cutaneous manifestations of the disorder. Characterization of these Lynch-related skin lesions could help in early recognition of patients with Lynch Syndrome. A broad search of the literature on OVID Medline and Embase was carried out to capture papers reporting cutaneous manifestations in Lynch Syndrome patients. The results were uploaded into Mendeley reference management software. The PRISMA workflow was used in the literature selection process. In this systematic review, data were collected from 961 cases from 413 studies, including 380 molecularly confirmed Lynch Syndrome cases. The main skin lesions were: Sebaceous adenomas (43%), sebaceous carcinomas (27%), keratoacanthomas (16%), sebaceomas (13%), squamous cell carcinomas (23%), and basal cell carcinomas (10%).\n                    <jats:italic>MSH2<\/jats:italic>\n                    variants were the most common underlying genotype (72%). Assessment of mismatch repair by immunohistochemistry, microsatellite instability analysis, or both were performed on 328 skin lesions from 220 (58%) molecularly confirmed cases. In those skin lesions, 95% of Immunohistochemistry and 90% of the microsatellite instability test results were concordant with the underlying genotype. Sebaceous skin lesions are well-recognised phenotypic features of Lynch Syndrome. Our results show that squamous and basal cell carcinomas are relatively common in patients with Lynch syndrome; however, available evidence cannot confirm that Lynch syndrome is causal. Immunohistochemistry and\/or microsatellite instability testing of skin tumours in patients with a family history of Lynch Syndrome-associated cancers may be a useful approach in identifying patients requiring referral to Clinical Genetics and\/or consideration of germline genetic testing for Lynch Syndrome.\n                  <\/jats:p>","DOI":"10.1007\/s10689-022-00319-8","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:24:51Z","timestamp":1669281891000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-1552","authenticated-orcid":false,"given":"Shahram","family":"Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-7075","authenticated-orcid":false,"given":"Hazel","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9527-0844","authenticated-orcid":false,"given":"Kara","family":"Heelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrina","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-9216","authenticated-orcid":false,"given":"Terri P.","family":"McVeigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"319_CR1","unstructured":"National Institute for Health and Clinical Excellence (2017) Molecular testing strategies for Lynch syndrome in people with colorectal cancer. NICE Diagnostics Guidance. https:\/\/www.nice.org.uk\/guidance\/dg27"},{"issue":"2","key":"319_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10689-018-00117-1","volume":"18","author":"LH Biller","year":"2019","unstructured":"Biller LH, Syngal S, Yurgelun MB (2019) Recent advances in Lynch syndrome. Fam Cancer. Springer 18(2):211\u2013219. https:\/\/doi.org\/10.1007\/s10689-018-00117-1","journal-title":"Fam Cancer. Springer"},{"issue":"4","key":"319_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10689-010-9373-2","volume":"9","author":"FC Da Silva","year":"2010","unstructured":"Da Silva FC, De Oliveira LP, Santos EM, Nakagawa WT, Junior SA, Valentin MD et al (2010) Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer. Springer 9(4):563\u2013570. https:\/\/doi.org\/10.1007\/s10689-010-9373-2","journal-title":"Fam Cancer. Springer"},{"issue":"2","key":"319_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1399-0004.2008.01125.x","volume":"75","author":"E Barrow","year":"2009","unstructured":"Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F et al (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75(2):141\u2013149. https:\/\/doi.org\/10.1111\/j.1399-0004.2008.01125.x","journal-title":"Clin Genet"},{"issue":"12","key":"319_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/jmg.2009.068122","volume":"46","author":"MP Hitchins","year":"2009","unstructured":"Hitchins MP, Ward RL (2009) Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. J Med Genet 46(12):793\u2013802. https:\/\/doi.org\/10.1136\/jmg.2009.068122","journal-title":"J Med Genet"},{"key":"319_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1388","volume":"356","author":"KJ Monahan","year":"2017","unstructured":"Monahan KJ, Alsina D, Bach S, Buchanan J, Burn J, Clark S et al (2017) Urgent improvements needed to diagnose and manage Lynch syndrome. BMJ (Clinical research ed) 356:j998. https:\/\/doi.org\/10.1136\/bmj.j1388","journal-title":"BMJ (Clinical research ed)"},{"key":"319_CR7","unstructured":"National Institute for Health and Clinical Excellence (2020) Testing strategies for Lynch syndrome in people with endometrial cancer. NICE Diagnostics Guidance. https:\/\/www.nice.org.uk\/guidance\/dg42\/chapter\/1-Recommendations"},{"issue":"1","key":"319_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0190-9622(95)90017-9","volume":"33","author":"RA Schwartz","year":"1995","unstructured":"Schwartz RA, Torre DP (1995) The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 33(1):90\u2013104. https:\/\/doi.org\/10.1016\/0190-9622(95)90017-9","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"319_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jaad.2015.09.074","volume":"74","author":"AM John","year":"2016","unstructured":"John AM, Schwartz RA (2016) Muir-Torre syndrome (MTS): an update and approach to diagnosis and management. J Am Acad Dermatol. Elsevier 74(3):558\u2013566. https:\/\/doi.org\/10.1016\/j.jaad.2015.09.074","journal-title":"J Am Acad Dermatol. Elsevier"},{"issue":"2","key":"319_CR10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/bjd.20139","volume":"185","author":"BLM Ykema","year":"2021","unstructured":"Ykema BLM, Adan F, Crijns MB, Bleeker FE, Dekker E, Bekkenk MW, Snaebjornsson P, van Leerdam ME (2021) Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours. Br J Dermatol 185(2):462\u2013463. https:\/\/doi.org\/10.1111\/bjd.20139","journal-title":"Br J Dermatol"},{"issue":"2","key":"319_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/bjd.16552","volume":"179","author":"F Adan","year":"2018","unstructured":"Adan F, Crijns M, Zandstra W, Bekkenk M, Bleeker F, Dekker E et al (2018) Cumulative risk of skin tumours in patients with Lynch syndrome. Br J Dermatol 179(2):522\u2013523. https:\/\/doi.org\/10.1111\/bjd.16552","journal-title":"Br J Dermatol"},{"issue":"5","key":"319_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/bjd.20970","volume":"186","author":"P Sowter","year":"2022","unstructured":"Sowter P, Santibanez-Koref M, Jackson M, Borthwick G, Burn J, Rajan N et al (2022) Response to \u2018cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours.\u2019 Br J Dermatol 186(5):913\u2013914. https:\/\/doi.org\/10.1111\/bjd.20970","journal-title":"Br J Dermatol"},{"issue":"2","key":"319_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1055\/s-0032-1313781","volume":"25","author":"BJ Bansidhar","year":"2012","unstructured":"Bansidhar BJ (2012) Extracolonic manifestations of Lynch syndrome. Clin Colon Rectal Surg 25(2):103\u2013110. https:\/\/doi.org\/10.1055\/s-0032-1313781","journal-title":"Clin Colon Rectal Surg"},{"issue":"34","key":"319_CR14","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1055\/s-2008-1068239","volume":"112","author":"U Karsten","year":"1987","unstructured":"Karsten U, Christophers E, Sterry W (1987) Das Torre-Muir-Syndrom: Talgdr\u00fcsentumoren signalisieren Kolonkarzinome und andere interne Malignome. Dtsch Med Wochenschr 112(34):1296\u20131301. https:\/\/doi.org\/10.1055\/s-2008-1068239","journal-title":"Dtsch Med Wochenschr"},{"key":"319_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jcol.2019.07.006","volume":"40","author":"MB Matos","year":"2020","unstructured":"Matos MB, Barbosa LE, Teixeira JP (2020) Narrative review comparing the epidemiology, characteristics, and survival in sporadic colorectal carcinoma\/Lynch syndrome. J Coloproctol (Rio J). SciELO Brasil 40:73\u201378. https:\/\/doi.org\/10.1016\/j.jcol.2019.07.006","journal-title":"J Coloproctol (Rio J). SciELO Brasil"},{"issue":"5","key":"319_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s0190-9622(99)70001-0","volume":"41","author":"S Akhtar","year":"1999","unstructured":"Akhtar S, Oza KK, Khan SA, Wright J (1999) Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol. Elsevier 41(5):681\u2013686. https:\/\/doi.org\/10.1016\/s0190-9622(99)70001-0","journal-title":"J Am Acad Dermatol. Elsevier"},{"issue":"8","key":"319_CR17","first-page":"978","volume":"93","author":"J Manonukul","year":"2010","unstructured":"Manonukul J, Kajornvuthidej S (2010) Sebaceous neoplasms in Siriraj Hospital, Mahidol University: a 9-year-retrospective study. J Med Assoc Thai 93(8):978\u2013991","journal-title":"J Med Assoc Thai"},{"issue":"12","key":"319_CR18","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.23963","volume":"113","author":"GM Dores","year":"2008","unstructured":"Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni JF Jr (2008) Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer 113(12):3372\u20133381. https:\/\/doi.org\/10.1002\/cncr.23963","journal-title":"Cancer"},{"issue":"2","key":"319_CR19","doi-asserted-by":"publisher","first-page":"pkaa020","DOI":"10.1093\/jncics\/pkaa020","volume":"4","author":"MR Sargen","year":"2020","unstructured":"Sargen MR, Mai ZM, Engels EA, Goldstein AM, Tucker MA, Pfeiffer RM, Cahoon EK (2020) Ambient ultraviolet radiation and sebaceous carcinoma incidence in the United States, 2000\u20132016. JNCI Cancer Spectr 4(2):pkaa020. https:\/\/doi.org\/10.1093\/jncics\/pkaa020","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"319_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.CCR-20-2473","volume":"27","author":"MR Sargen","year":"2021","unstructured":"Sargen MR, Starrett GJ, Engels EA, Cahoon EK, Tucker MA, Goldstein AM (2021) Sebaceous carcinoma epidemiology and genetics: emerging concepts and clinical implications for screening, prevention, and treatment. Clin Cancer Res 27(2):389\u2013393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2473","journal-title":"Clin Cancer Res"},{"key":"319_CR21","unstructured":"British Association of Dermatologists (2022). New data shows a record 224,000 skin cancers in England in 2019. British Association of Dermatologists. https:\/\/www.bad.org.uk\/new-data-shows-a-record-224000-skin-cancers-in-england-in-2019\/. Accessed 13 October 2022."},{"issue":"1","key":"319_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cncr.23952","volume":"115","author":"T Dasgupta","year":"2008","unstructured":"Dasgupta T, Wilson L, Yu J (2008) A retrospective review of 1349 cases of sebaceous carcinoma. Cancer 115(1):158\u2013165. https:\/\/doi.org\/10.1002\/cncr.23952","journal-title":"Cancer"},{"issue":"11","key":"319_CR23","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1111\/jdv.13703","volume":"30","author":"J Callens","year":"2016","unstructured":"Callens J, Van Eycken L, Henau K, Garmyn M (2016) Epidemiology of basal and squamous cell carcinoma in Belgium: the need for a uniform and compulsory registration. J Eur Acad Dermatol Venereol 30(11):1912\u20131918. https:\/\/doi.org\/10.1111\/jdv.13703","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"319_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.sder.2012.08.005","volume":"31","author":"V Nikolaou","year":"2012","unstructured":"Nikolaou V, Stratigos AJ, Tsao H (2012) Hereditary nonmelanoma skin cancer. Semin Cutan Med Surg 31(4):204\u2013210. https:\/\/doi.org\/10.1016\/j.sder.2012.08.005","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"319_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/gcc.22804","volume":"59","author":"C Vermaut","year":"2019","unstructured":"Vermaut C, Leclerc J, Vasseur F, Wacrenier A, Lovecchio T, Boidin D et al (2019) MSH2 c.1022T>C, p.Leu341Pro is a founder pathogenic variation and a major cause of Lynch syndrome in the North of France. Genes Chromosom Cancer 59(2):111\u2013118. https:\/\/doi.org\/10.1002\/gcc.22804","journal-title":"Genes Chromosom Cancer"},{"issue":"3","key":"319_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00428-016-2052-4","volume":"470","author":"J Lobo","year":"2016","unstructured":"Lobo J, Pinto C, Freitas M, Pinheiro M, Vizcaino R, Oliva E et al (2016) Ovarian metastasis from uveal melanoma with MLH1\/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence? Virchows Arch 470(3):347\u2013352. https:\/\/doi.org\/10.1007\/s00428-016-2052-4","journal-title":"Virchows Arch"},{"issue":"5","key":"319_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/BF03256208","volume":"10","author":"SE Gray","year":"2006","unstructured":"Gray SE, Kay EW, Leader M, Mabruk MJEMF (2006) Enhanced detection of microsatellite instability and mismatch repair gene expression in cutaneous squamous cell carcinomas. Mol Diagn Ther 10(5):327\u2013334. https:\/\/doi.org\/10.1007\/BF03256208","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"319_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/path.5422","volume":"250","author":"G Cerretelli","year":"2020","unstructured":"Cerretelli G, Ager A, Arends M, Frayling I (2020) Molecular pathology of Lynch syndrome. J Pathol 250(5):518\u2013531. https:\/\/doi.org\/10.1002\/path.5422","journal-title":"J Pathol"},{"issue":"9","key":"319_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/gim.2014.19","volume":"16","author":"M Roberts","year":"2014","unstructured":"Roberts M, Riegert-Johnson D, Thomas B, Rumilla K, Thomas C, Heckman M et al (2014) A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. Genet Med 16(9):711\u2013716. https:\/\/doi.org\/10.1038\/gim.2014.19","journal-title":"Genet Med"},{"issue":"26","key":"319_CR30","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"319_CR31","unstructured":"U.S. Food and Drug Administration (2017) FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication. Accessed 11 July 2022."},{"issue":"4","key":"319_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD et al (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379(4):341\u2013351. https:\/\/doi.org\/10.1056\/NEJMoa1805131","journal-title":"N Engl J Med"},{"issue":"6","key":"319_CR33","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","volume":"22","author":"AJ Stratigos","year":"2021","unstructured":"Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M et al (2021) Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 22(6):848\u2013857. https:\/\/doi.org\/10.1016\/S1470-2045(21)00126-1","journal-title":"Lancet Oncol"},{"key":"319_CR34","unstructured":"European Medicines Agency (2019) Libtayo. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libtayo. Accessed 11 July 2022."},{"key":"319_CR35","unstructured":"U.S. Food and Drug Administration (2019) FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma. Accessed 11 July 2022."},{"key":"319_CR36","unstructured":"U.S. Food and Drug Administration (2021) FDA approves cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma. U.S. Food and Drug Administration https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-cemiplimab-rwlc-locally-advanced-and-metastatic-basal-cell-carcinoma. Accessed 11 July 2022."}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-022-00319-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-022-00319-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-022-00319-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T05:21:50Z","timestamp":1678944110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-022-00319-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s10689-022-00319-8","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}